동반진단 시장 기회, 성장 촉진요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Companion Diagnostics Market was valued at USD 7.9 billion in 2025 and is estimated to grow at a CAGR of 11.2% to reach USD 22.5 billion by 2035.

Growth in the Companion Diagnostics Market is fueled by the increasing prevalence of cancer, the rising occurrence of adverse drug reactions, and the expanding adoption of precision medicine across healthcare systems. Companion diagnostics are specialized medical tests designed to determine which patients are most likely to respond to a targeted therapy or may face a greater risk of treatment-related adverse effects. These diagnostic solutions identify biomarkers, genetic alterations, and protein expression patterns that support personalized treatment selection and improve clinical decision-making. Their growing role in precision medicine has significantly increased their importance in modern healthcare, particularly for therapies that require biomarker-guided patient selection. As cancer cases continue to increase worldwide, healthcare providers are placing greater emphasis on accurate molecular testing to improve treatment effectiveness and patient outcomes. The ongoing transition from standardized treatment approaches toward personalized healthcare strategies is further strengthening market demand, as biomarker-based diagnostics enable more precise therapeutic interventions and contribute to better clinical results while supporting the continued advancement of targeted medicine.

The consumables segment accounted for a 62.1% share in 2025. This segment includes assay kits, reagents, antibodies, probes, cartridges, and other testing materials required during companion diagnostic procedures. These products serve as essential components of molecular and genetic testing workflows by enabling the identification of biomarkers, gene mutations, and other disease-specific characteristics used to guide targeted treatment decisions. Their importance continues to increase as biomarker-driven testing becomes an integral part of precision medicine, supporting accurate patient selection and personalized therapeutic strategies across a wide range of clinical applications.

The pharmaceutical and biopharmaceutical companies segment held 38.3% share in 2025. These organizations integrate companion diagnostics throughout multiple stages of the drug development process to identify appropriate patient populations and support the advancement of targeted therapies. The increasing use of biomarker-based approaches within clinical development programs is helping improve treatment effectiveness, optimize clinical trial performance, and support regulatory approval efforts, contributing to continued demand for companion diagnostic technologies.

North America Companion Diagnostics Market held a 33.3% share in 2025. Rising concerns regarding adverse drug reactions are encouraging broader adoption of companion diagnostic solutions throughout the region. Biomarker-based testing enables healthcare providers to identify patients who are more likely to benefit from specific therapies while minimizing the risk of treatment-related complications. The growing emphasis on personalized healthcare and precision treatment approaches continues to strengthen demand for companion diagnostics across the North American market.

Major companies operating in the Global Companion Diagnostics Market include F. Hoffmann-La Roche Ltd, Foundation Medicine, QIAGEN, Agilent Technologies, Abbott Laboratories, Illumina, Thermo Fisher Scientific, Guardant Health, Myriad Genetics, BioMerieux, Leica Biosystems, MolecularMD, ARUP Laboratories, Bio-Rad Laboratories, and Sysmex Corporation. Companies participating in the Companion Diagnostics Market are reinforcing their market position by investing in biomarker discovery, expanding molecular diagnostic capabilities, and strengthening research and development activities. Many organizations are focusing on developing advanced diagnostic assays that support precision medicine and improve targeted therapy selection. Strategic collaborations between diagnostic developers and pharmaceutical companies are accelerating the co-development of companion diagnostics alongside innovative therapies, helping expand commercial opportunities and improve regulatory success.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy and data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail and confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Forecast model
  • 1.7.1 Quantified market impact analysis
    • 1.7.1.1 Mathematical impact of growth parameters on forecast
• 1.8 Research transparency addendum
  • 1.8.1 Source attribution framework
  • 1.8.2 Quality assurance metrics
  • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 3600 synopsis
• 2.2 Key market trends
  • 2.2.1 Product trends
  • 2.2.2 Therapy area trends
  • 2.2.3 Technology trends
  • 2.2.4 End use trends
  • 2.2.5 Regional trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cancer.
    • 3.2.1.2 Growing incidence of adverse drug reaction.
    • 3.2.1.3 Growth of precision medicine.
    • 3.2.1.4 Pharmaceutical firms increasingly embed companion drugs in drug development.
    • 3.2.1.5 Rising ADC and immuno-oncology drug approvals requiring companion diagnostics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High development costs.
    • 3.2.2.2 Limited reimbursement models.
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing adoption of liquid biopsy-based companion diagnostics
    • 3.2.3.2 Expansion of companion diagnostics for emerging biomarker targets (HER2-ultralow, KRAS G12C, FGFR alterations, and NTRK gene fusions)
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technology landscape (Driven by primary research)
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends (Driven by primary research)
• 3.7 Impact of AI and Generative AI on the market (Driven by primary research)
• 3.8 Patent analysis
• 3.9 Pricing trend analysis (Driven by primary research)
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
  • 4.2.4 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments
• 5.3 Consumables
• 5.4 Software and services

Chapter 6 Market Estimates and Forecast, By Therapy Areas, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Cancer
  • 6.2.1 Breast cancer
  • 6.2.2 Lung cancer
  • 6.2.3 Colorectal cancer
  • 6.2.4 Skin cancer
  • 6.2.5 Other cancers
• 6.3 Cardiovascular disease
• 6.4 Neurological diseases
• 6.5 Other therapy areas

Chapter 7 Market Estimates and Forecast, By Technology, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Immunohistochemistry
• 7.3 In situ hybridization
• 7.4 Polymerase chain reaction
• 7.5 Next-Generation Sequencing
• 7.6 Other technologies

Chapter 8 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Pharmaceutical and biopharmaceutical companies
• 8.4 Contract research organizations
• 8.5 Diagnostic laboratories

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 F. Hoffmann-La Roche Ltd
• 10.2 Foundation Medicine
• 10.3 QIAGEN
• 10.4 Agilent Technologies
• 10.5 Abbott Laboratories
• 10.6 Illumina
• 10.7 Thermo Fisher Scientific
• 10.8 Guardant Health
• 10.9 Myriad Genetics
• 10.10 BioMerieux
• 10.11 Leica Biosystems
• 10.12 MolecularMD
• 10.13 ARUP Laboratories
• 10.14 Bio-Rad Laboratories
• 10.15 Sysmex Corporation